Skip to Content

Join the 'Cabometyx' group to help and get support from people like you.

Cabometyx News

For Seniors, Treatment for One Eye Disease May Cause Another

Posted 16 Mar 2017 by Drugs.com

THURSDAY, March 16, 2017 – Drugs that preserve vision in people with the eye disease called age-related macular degeneration might increase the risk of another eye condition – glaucoma, a new study suggests. People who received at least seven eye injections of the drug bevacizumab (Avastin) each year to treat macular degeneration have a higher risk of eventually needing surgery to treat glaucoma, the Canadian study found. But, the researchers aren't suggesting that people forgo these treatments for macular degeneration. These drugs help stave off a previously untreatable cause of blindness in the elderly, and should continue to be used, the researchers said. And, if glaucoma does develop, treatments are available. "Even though there may be a risk here, this doesn't mean you should not be getting injections for macular degeneration," said study lead author Dr. Brennan Eadie. He's an ... Read more

Related support groups: Eye Conditions, Glaucoma, Macular Degeneration, Glaucoma (Open Angle), Votrient, Avastin, Sutent, Nexavar, Pazopanib, Stivarga, Sunitinib, Glaucoma/Intraocular Hypertension, Retinal Disorders, Cyramza, Sorafenib, Bevacizumab, Vandetanib, Cabometyx, Lenvima, Retinopathy

Cancer's Heavy Financial Burden

Posted 8 Jun 2016 by Drugs.com

WEDNESDAY, June 8, 2016 – Many cancer patients can't afford to see their doctor or take the medications they've been prescribed, a new study finds. And the problem will likely only get worse as the cost of cancer treatments continues to rise, the study authors said. "You can prescribe the best drug in the world, but if patients can't afford it and they can't get it, then it won't be effective," said study author Dr. Greg Knight. He is chief fellow with the University of North Carolina School of Medicine's division of hematology and oncology. "We saw a significant portion of patients in our study who were stretching their prescriptions or not coming to the doctor's office," Knight said in a university news release. The researchers reviewed survey results from nearly 2,000 patients at the N.C. Cancer Hospital in Chapel Hill, N.C. The participants were all 18 and older, and had been ... Read more

Related support groups: Cancer, Breast Cancer, Prostate Cancer, Lung Cancer, Gleevec, Colorectal Cancer, Votrient, Brain Tumor, Tarceva, Avastin, Melanoma, Skin Cancer, Tasigna, Ovarian Cancer, Sutent, Endometrial Cancer, Sprycel, Herceptin, Afinitor, Nausea/Vomiting - Chemotherapy Induced

U.S. Pays Highest Prices for Cancer Meds: Study

Posted 6 Jun 2016 by Drugs.com

MONDAY, June 6, 2016 – The United States pays the highest prices in the world for generic and brand-name cancer drugs, a new study has found. However, as the world's wealthiest nation, the United States is better able to pay for those pricey drugs than poorer countries with somewhat lower medication prices, added study lead author Dr. Daniel Goldstein. People in China and India are much less able to afford cancer drugs than Americans, he said, even though U.S. monthly drug prices are about three to six times higher in the United States. That doesn't mean America came out on top in overall drug affordability, however. Developed nations such as Australia, England and Israel had the "best deal" in the world on cancer drugs, thanks to government programs that regulate drug pricing, the study found. "America is the wealthiest nation, but its drug prices are significantly higher – so much ... Read more

Related support groups: Cancer, Provera, Depo-Provera, Methotrexate, Breast Cancer, Accutane, Lupron, Medroxyprogesterone, Tamoxifen, Arimidex, Tretinoin, Fluorouracil, Lupron Depot, Femara, Lung Cancer, Gleevec, Rituxan, Isotretinoin, Colorectal Cancer, Votrient

Exelixis Announces FDA Approval of Cabometyx (cabozantinib) for Patients with Advanced Renal Cell Carcinoma

Posted 27 Apr 2016 by Drugs.com

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Apr. 25, 2016-- Exelixis, Inc. (NASDAQ:EXEL) today announced that the U.S. Food and Drug Administration (FDA) has approved Cabometyx (cabozantinib) tablets for the treatment of patients with advanced renal cell carcinoma (RCC) who have received prior anti-angiogenic therapy. RCC is the most common form of kidney cancer in adults. Cabometyx, which was granted Fast Track and Breakthrough Therapy designations by the FDA, is the first therapy to demonstrate in a phase 3 trial for patients with advanced RCC, robust and clinically meaningful improvements in all three key efficacy parameters — overall survival, progression-free survival and objective response rate. “With today’s announcement, patients with previously treated advanced kidney cancer now have a new option, the first and only approved product demonstrated to help patients live longer w ... Read more

Related support groups: Renal Cell Carcinoma, Cabometyx, Cabozantinib

Ask a Question

Further Information

Related Condition Support Groups

Renal Cell Carcinoma

Cabometyx Patient Information at Drugs.com